CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report)'s share price traded down 8.7% during mid-day trading on Monday . The company traded as low as $33.05 and last traded at $33.76. 679,792 shares were traded during trading, a decline of 56% from the average session volume of 1,549,634 shares. The stock had previously closed at $36.99.
Analyst Ratings Changes
A number of equities analysts recently weighed in on CRSP shares. Chardan Capital dropped their price target on CRISPR Therapeutics from $94.00 to $84.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. Bank of America decreased their price objective on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating for the company in a research note on Tuesday, January 7th. Needham & Company LLC restated a "buy" rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, February 12th. Barclays raised their target price on CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 12th. Finally, JMP Securities reissued a "market outperform" rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $73.11.
Get Our Latest Stock Analysis on CRSP
CRISPR Therapeutics Trading Down 0.0 %
The firm has a market cap of $2.80 billion, a price-to-earnings ratio of -7.47 and a beta of 1.85. The stock has a fifty day moving average price of $42.37 and a 200 day moving average price of $44.82.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. On average, sell-side analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current year.
Insider Buying and Selling
In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 2,850 shares of CRISPR Therapeutics stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $120,897.00. Following the transaction, the general counsel now directly owns 77,530 shares of the company's stock, valued at $3,288,822.60. The trade was a 3.55 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Julianne Bruno sold 1,198 shares of the stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $50,819.16. Following the completion of the sale, the chief operating officer now directly owns 8,263 shares of the company's stock, valued at $350,516.46. This represents a 12.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 32,381 shares of company stock valued at $1,608,243. Insiders own 4.10% of the company's stock.
Hedge Funds Weigh In On CRISPR Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in CRSP. Wood Tarver Financial Group LLC bought a new stake in CRISPR Therapeutics in the 4th quarter valued at $30,000. Ameriflex Group Inc. bought a new position in CRISPR Therapeutics during the fourth quarter worth about $36,000. Highline Wealth Partners LLC bought a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at approximately $39,000. Western Pacific Wealth Management LP raised its holdings in shares of CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock worth $39,000 after buying an additional 500 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new position in shares of CRISPR Therapeutics during the 3rd quarter worth approximately $40,000. 69.20% of the stock is currently owned by institutional investors.
About CRISPR Therapeutics
(
Get Free Report)
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Featured Stories
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
